Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare PartnershipBOZEN, Italy - Health Robotics today reported that on the heels of its recent partnership announcement with McKesson, it has received categorical support from virtually all of its 13 North American customers in just a few days since the partnership was publicly announced. While several customers’ hospital policies prevent them from publicly commenting on industry events, a few reactions to the McKesson-Health Robotics partnership [CytoCare Robot only] were cleared for publication. Charlie Buckwell Appointed Medical Communications Head, Further Advancing McCann Healthcare Worldwide’s Global CapabilitiesNEW YORK - McCann Healthcare Worldwide is re-aligning and expanding its medical communications businesses, to build a dedicated, unified and empowered medical communications network capability, with truly global reach. Chemist+Druggist Reveals Frontline NHS Staff Won’t Get Swine Flu VaccineTONBRIDGE, England - Pharmacists have branded government swine flu vaccination plans “unacceptable,” Chemist+Druggist has revealed. The criticism comes after the profession was excluded from the first wave of healthcare staff to get the jab. Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & SullivanLONDON - Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change. Clinical Study Proves Pollogen’s TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch MarksTEL AVIV, Israel - - Results Published in the Online Edition of the Journal of Dermatological Treatment Elsevier Global Medical News Launches H1N1 ChannelMORRISTOWN, New Jersey - An H1N1 influenza channel has been added to the Elsevier Global Medical News (EGMN) wire service division of the International Medical News Group. The H1N1 channel was created to meet physicians’ continuing needs to keep up-to-date with the news about the spread of the 2009 H1N1 influenza virus, as well as the new diagnostics, vaccines, clinical trials, and treatments for H1N1 infections. Epix Pharmaceuticals, Inc. Announces the PRX-08066 Therapeutics Program in Phase 2 for Respiratory Indication Will Be Part of The Intellectual Property Offered for Sale at the September 30, 2009 AuctionWELLESLEY HILLS, Massachusetts - Joseph F. Finn, Jr., C.P.A. (”Finn”), announced today that the PRX-08066 Therapeutics Program in Phase 2 for respiratory indication will be part of the intellectual property offered for sale at the September 30, 2009 auction. D-Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering (IPO) on the Tel Aviv Stock Exchange (TASE)REHOVOT, Israel - D-Pharm announced today the completion of a financial round, which yielded NIS 85 million (approximately $23M USD) to fund the Company’s late stage clinical stroke program. The financial round combined a rights offering of NIS 57 million and an Initial Public Offering (IPO) of NIS 28 million. The IPO was oversubscribed and the unit price was set at 133 NIS, 13% higher than the minimum price. The company’s pre-money valuation was NIS 120 million. Gregorio Maranon Foundation Pioneers the Prevention of Pediatric Errors as the 1st European Installation of i.v.STATION(TM)BOZEN, Italy - Health Robotics today announced that it has reached an agreement with Gregorio Maranon Foundation to sell and install its revolutionary i.v.STATION robot at the GMU Hospital this October, concurrent with the nine American i.v.STATION installations at Duke University, MD Anderson Cancer Center, Brigham & Women’s, Univ. of Pennsylvania, Univ. of Southern California, Fairview-University of Minnesota, Ochsner Clinic, Allegiance Health, and Univ. of Colorado. Helix BioPharma Announces the Appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its Board of DirectorsAURORA, Ontario - Helix BioPharma Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced the appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its board of directors. Professor Roszkowski-Sliz is replacing Professor Slawomir Majewski, who has stepped down from the board to assume the advisory role of European medical director for Helix. Eiger BioPharmaceuticals Appoints Paul Truex to Board of DirectorsPALO ALTO, California - - Industry Veteran with Business Development and Transactional Expertise Joins Eiger Board of Directors PharmaTelevision Launches the First Daily News Show for the Life Sciences IndustryOXFORD, England - PharmaTelevision(R), the authoritative channel for the pharmaceutical, biotechnology and related industries, announced today the launch of its new service PharmaTelevision News (PTV News), the World’s first daily television news and analysis programme for the sector. Amsterdam Molecular Therapeutics Reports Half Year Results 2009AMSTERDAM - - Conference Call & Webcast Today at 2:00 p.m. CET Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2009. Altacor Beats Biotech Funding DroughtCAMBRIDGE, England - Ophthalmology development and marketing company Altacor has announced closing of a GBP1m first tranche of Series B funding. The round was led by two new institutional investors, Esperante and the Aspire Fund, whilst existing investors Beringea’s Proven VCT and angel investors also participated. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion TechnologiesHONG KONG and LAKE ZURICH, Illinois - Fenwal, Inc. of Lake Zurich, Illinois, and Golden Meditech (stock code: 801.HK) of Hong Kong, announced today they have agreed to form a joint venture in China to focus on blood collection and transfusion products for the fast-growing Chinese medical market. Nanosyn, Inc. and PCAS Announce the Signing of a Joint-Venture Agreement to Operate PCAS-NANOSYN, LLCLONGJUMEAU, PARIS and MENLO PARK, California - PCAS, a worldwide leader in commercial scale pharmaceutical synthesis and fine and specialty chemical manufacturing, and Nanosyn, a leading US based pharmaceutical contract research provider of preclinical chemistry and biology services, announce the signing of a joint-venture agreement to operate PCAS-NANOSYN, LLC, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California. Ingenuity’s Technology Powers BD Cell Pathways Tool on New BD Biosciences WebsiteREDWOOD CITY, California - - Ingenuity’s contextual search capabilities and dynamic gene-based content will help BD Biosciences’ customers find relevant products and plan experiments Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b TrialPALO ALTO, California - - Proof of Concept Study Investigating NS4B-RNA Binding Inhibitor McKesson Expands Pharmacy Automation Product Portfolio to Include I.V. TherapyBOZEN, Italy - - Strategic Partnership Announced With Health Robotics Health Robotics today announced that it has signed an exclusive five-year strategic partnership with McKesson for Health Robotics’ CytoCare Robot. The agreement enables McKesson to achieve its goal of safely, accurately and cost-effectively automating the preparation of Oncology I.V. admixtures. Shire plc: Core Portfolio of Products Delivers 20% Sales GrowthLONDON - - 2009 Guidance Framework Reaffirmed Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2009. ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine DeliveryHALIFAX, Canada - ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, has signed an agreement with UK-based Scancell Ltd., the operating company of Scancell Holdings Plc (SCLP.PL), which is developing therapeutic cancer and infectious disease vaccines. This research agreement will explore the potential of using IVT’s DepoVax(TM) delivery system for Scancell’s novel ImmunoBody(R) DNA vaccines. Novel Chemotherapy Agent Bendamustine Significantly More Effective First-Line Therapy Than Chlorambucil in CLLCAMBRIDGE, England - - Blood Marrow Normalised in 31% (Versus 2%) of Patients, With Manageable Side-Effects Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford UniversityPALO ALTO, California - Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety of novel targets, including key features of NS4B, a non-structural protein in the HCV genome, which binds to HCV-RNA and is required for viral replication. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDALEXINGTON, Massachusetts - - Treatment Protocol Accepted and Rolling Submission of New Drug Application Initiated Hoya Announces First Quarter Financial Results for FY2010TOKYO, Japan - HOYA Corporation today announced financial results for the first quarter ended June 30, 2009. Net sales were 94.9 billion yen for the quarter, a 27.0% decrease from 130.1 billion yen in the same period last year, and operating income was 9.2 billion yen, a 57.5% decrease from 21.8 billion yen in the same period last year, mainly due to order decrease and the impact of exchange rates. Since April, however, there has been a degree of recovery noted in orders, which resulted in an increase of both net sales and operating income compared to the fourth quarter FY2009 ended March 31, 2009. The European Commission Approves Samsca(TM) (tolvaptan), Europe’s First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)TOKYO, Japan and UXBRIDGE, England - Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced today that the European Commission has approved the Marketing Authorisation Application for the company’s oral once-daily medication Samsca(TM)(tolvaptan), a selective V2-vasopressin receptor antagonist, for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in adults. Samsca is the first oral vasopressin receptor antagonist available in Europe. “Over the Next 2-3 Years We Will Leverage Developmental Capabilities and Explore In-licensing and a Co-development Model to Consolidate Our Presence in Japan” - Dr. Kailash Sharma, President, Japan Operations, Zydus CadilaTOKYO - With a business plan to launch 8-10 new products each year, Nippon Universal Pharmaceutical Co. Ltd., a subsidiary of the Zydus group, one of India’s leading integrated pharma companies & a global healthcare provider, is looking to give a big boost to its operations in the Japanese generic market which is still evolving. While the total pharma market in Japan is estimated at $ 60 bn the generic market is only about 6% of this in value terms and just 18% in volume, which is very low compared to highly genericised markets like USA and Europe. The awareness of generics in Japan is comparatively low and generics are still largely perceived as cheaper, low quality alternatives to patented drugs. The nationwide promotion and awareness campaign regarding the safety and efficacy of generics however is expected to change this perception and usage in future. Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine LitigationTAINAN, Taiwan - Eli Lilly & Company (”Lilly”) and ScinoPharm Taiwan Ltd. (”ScinoPharm”) announced today that they have reached an amicable resolution of all ongoing patent litigations between the companies relating to ScinoPharm’s manufacture and sale of gemcitabine hydrochloride around the world. FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and AdolescentsPHILADELPHIA - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Complete Response letter today for INTUNIV(TM) (guanfacine) Extended Release from the Food and Drug Administration (FDA). This decision comes following labeling discussions with the FDA that did not result in agreement in time to meet the PDUFA date. Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSKCOPENHAGEN, Denmark - Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline. Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory BoardCAMBRIDGE, Massachusetts - Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced that David Julius, PhD, professor and chair of the department of physiology at the University of California, San Francisco, and a leading pioneer in the pathophysiology of pain, has joined Solace’s scientific advisory board. European CHMP Issues Positive Opinion on Wyeth’s TORISEL for Treatment of Relapsed/Refractory Mantle Cell LymphomaMAIDENHEAD, England - Wyeth Europa, a division of Wyeth (NYSE:WYE), announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recommending the approval of the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of relapsed and/or refractory mantle cell lymphoma (MCL). The CHMP’s opinion will now be forwarded to the European Commission for a final decision. MCL is a rare type of non-Hodgkin’s lymphoma (NHL) that accounts for approximately 6 percent of NHL cases and has the lowest five-year survival of any type of lymphoma. TORISEL received Orphan Medicinal Product designation for the treatment of MCL in the European Union (EU) in November 2006. Movetis Receives Positive Opinion by the CHMP on European Marketing Authorisation Application for Resolor(R) (prucalopride) Indicated for the Treatment of Chronic ConstipationTURNHOUT, Belgium - Movetis, the GI specialty pharmaceutical company based in Belgium announces today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) on the European Marketing Authorisation Application (MAA) for its lead product, prucalopride for the treatment of chronic constipation (CC). Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone GraftsKEELE, England - A recent independent study has confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics Company, Biocomposites, ( www.biocomposites.com), as an effective bone replacement material demonstrating superior bone regenerative properties due to its unique negative zeta potential control (ZPC(TM)). Approval of Instanyl(R) Marks Important Turn in Management of Breakthrough Cancer PainTAASTRUP, Denmark - - First Intranasal Treatment for Breakthrough Cancer Pain Allowing Patients Fast, Effective and Good Tolerated Pain Relief Soon to be Available |
